A detailed history of Trexquant Investment LP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 51,296 shares of VKTX stock, worth $3.23 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
51,296
Holding current value
$3.23 Million
% of portfolio
0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$47.39 - $80.2 $2.43 Million - $4.11 Million
51,296 New
51,296 $2.72 Million
Q3 2023

Nov 13, 2023

SELL
$10.92 - $16.0 $1.99 Million - $2.91 Million
-182,172 Reduced 68.4%
84,147 $931,000
Q2 2023

Aug 11, 2023

BUY
$14.84 - $24.79 $2.93 Million - $4.89 Million
197,394 Added 286.39%
266,319 $4.32 Million
Q1 2023

May 15, 2023

SELL
$8.08 - $17.33 $335,231 - $719,004
-41,489 Reduced 37.58%
68,925 $1.15 Million
Q4 2022

Feb 13, 2023

BUY
$2.72 - $9.4 $300,326 - $1.04 Million
110,414 New
110,414 $1.04 Million
Q1 2022

May 13, 2022

SELL
$3.0 - $4.88 $56,142 - $91,324
-18,714 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$4.6 - $6.72 $386 - $564
84 Added 0.45%
18,714 $86,000
Q3 2021

Nov 12, 2021

SELL
$5.58 - $7.04 $14,904 - $18,803
-2,671 Reduced 12.54%
18,630 $117,000
Q2 2021

Aug 12, 2021

BUY
$5.19 - $6.73 $110,552 - $143,355
21,301 New
21,301 $128,000
Q1 2021

May 13, 2021

SELL
$5.74 - $9.67 $113,198 - $190,702
-19,721 Closed
0 $0
Q4 2020

Feb 11, 2021

SELL
$5.3 - $6.71 $221,020 - $279,820
-41,702 Reduced 67.89%
19,721 $111,000
Q3 2020

Nov 06, 2020

BUY
$5.73 - $8.11 $351,953 - $498,140
61,423 New
61,423 $357,000
Q2 2018

Aug 07, 2018

SELL
$3.88 - $12.74 $249,922 - $820,621
-64,413 Closed
0 $0
Q1 2018

May 03, 2018

BUY
$4.11 - $6.93 $264,737 - $446,382
64,413 New
64,413 $281,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.83B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.